Policy
Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request.
1. For individuals with acute or persistent classic symptoms of diabetes mellitus, measurement of plasma glucose is considered MEDICALLY
NECESSARY.
2. For individuals with a diagnosis of either Type 1 or Type 2 diabetes mellitus, measurement of hemoglobin A1c is considered MEDICALLY
NECESSARY in any of the following situations:
a. Upon initial diagnosis to establish a baseline value and to determine treatment goals.
b. Twice a year (every 6 months) in individuals who are meeting treatment goals and who, based on daily glucose monitoring, appear to have
stable glycemic control.
c. Quarterly in individuals who are not meeting treatment goals for glycemic control.
d. Quarterly in individuals whose pharmacologic therapy has changed.
e. Quarterly for individuals who are pregnant.
3. For prediabetic individuals, annual screening for type 2 diabetes with a fasting plasma glucose test or measurement of hemoglobin A1c is
considered MEDICALLY NECESSARY.
4. For asymptomatic individuals who are 35 years of age or older and who have no risk factors for diabetes, screening for prediabetes or type 2
diabetes once every three years with a fasting plasma glucose test is considered MEDICALLY NECESSARY.
5. For individuals 18 years of age or older, screening once every three years for prediabetes or type 2 diabetes with a fasting plasma glucose test or
measurement of hemoglobin A1c is considered MEDICALLY NECESSARY for individuals with any of the following risk factors:
a. For individuals who are overweight or obese.
b. For first-degree relatives (see Note 1) of individuals with diabetes.
c. For individuals with a history of cardiovascular disease.
d. For individuals with hypertension.
e. For individuals with hypercholesterolemia.
f. For individuals with metabolic syndrome.
g. For individuals who are obese and have acanthosis nigricans.
h. For individuals with polycystic ovary syndrome.
i. For individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
j. For individuals who were previously diagnosed with gestational diabetes mellitus (GDM).
6. For individuals who are positive for HIV, screening for diabetes and prediabetes with a fasting plasma glucose test is considered MEDICALLY
NECESSARY in any of the following situations:
a. For individuals starting antiretroviral therapy (ART).
b. For individuals switching their ART.
c. 3-6 months after starting or switching antiretroviral therapy.
d. Annually when screening results were initially normal.
7. For individuals 10 years of age and older who have been diagnosed with cystic fibrosis (CF) but not with CF-related diabetes, annual screening
for CF-related diabetes with an OGTT is considered MEDICALLY NECESSARY.
8. For overweight or obese individuals less than 18 years of age, diabetes screening once every three years with a fasting plasma glucose test, an
OGTT, or measurement of hemoglobin A1c is considered MEDICALLY NECESSARY for individuals with any of the following risk factors:
a. The individual has a maternal history of diabetes or gestational diabetes mellitus during the child’s gestation.
b. The individual has a family history of Type 2 diabetes in first- or second-degree relatives (see Note 1).
c. The individual has signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension,
dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight).
9. For pregnant individuals, a fasting plasma glucose test or an OGTT up to once per month during pregnancy is considered MEDICALLY
NECESSARY.
10. For individuals diagnosed with GDM during pregnancy, an OGTT is considered MEDICALLY NECESSARY in any of the following situations:
a. To screen for persistent diabetes or prediabetes 4-12 weeks postpartum.
b. For individuals with a positive initial postpartum screening result, repeat screening to confirm a diagnosis of persistent diabetes or
prediabetes.
11. For all other situations not addressed above, fasting plasma glucose testing at a wellness visit with no abnormal findings is considered
NOT MEDICALLY NECESSARY.
